SI-BONE Q2 Revenue Climbs 15%, Loss Narrows; CEO Adopts 10b5-1 Plan
SIBN sits 61% above its 52-week low of $11.48 on elevated volume (1.9× avg).
Summary
SI-BONE's Q2 2026 revenue rose 15.2% to $56 million, beating estimates, and the net loss narrowed. The CEO adopted a 10b5-1 plan for up to 492,961 shares, and the DOJ investigation continues.
Key Events · Earnings and Guidance · SIBN
-
Q2 Revenue Beats Estimates
Revenue of $56.0 million, up 15.2% year-over-year, driven by a 14.9% increase in U.S. procedure volumes.
-
Net Loss Narrows
Net loss improved to $4.1 million from $6.2 million a year ago, with gross margin at 79.5%.
-
Strong Cash Position
Cash and marketable securities totaled $145.9 million as of June 30, 2026, providing ample runway.
-
CEO Adopts 10b5-1 Trading Plan
CEO Laura Francis adopted a Rule 10b5-1 plan on May 21, 2026, covering up to 492,961 shares, expiring August 31, 2027.
Analysis · SIBN · Industrial Applications And Services
A strong second quarter saw SI-BONE's revenue climb 15.2% to $56 million, topping the August 3 consensus estimate of $55.34 million. The net loss narrowed to $4.1 million from $6.2 million a year ago, while gross margins held firm at 79.5%. The company had already raised full-year guidance in the earlier 8-K, and this 10-Q confirms the underlying financial health with $145.9 million in cash and marketable securities. However, CEO Laura Francis adopted a 10b5-1 trading plan covering up to 492,961 shares, which could create an overhang. The DOJ investigation into meals and consulting payments to healthcare professionals remains unresolved, with no accrual recorded.
At the time of this filing, SIBN was trading at $18.44 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $817.8M. The 52-week trading range was $11.48 to $21.89. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.